|1.||List, James F: 13 articles (10/2014 - 04/2009)|
|2.||Parikh, S: 12 articles (11/2015 - 10/2011)|
|3.||Parikh, Shamik: 9 articles (03/2015 - 09/2011)|
|4.||Sugg, Jennifer: 8 articles (07/2015 - 03/2012)|
|5.||Langkilde, A M: 8 articles (11/2014 - 10/2011)|
|6.||Sugg, J: 7 articles (11/2015 - 11/2012)|
|7.||Ptaszynska, Agata: 7 articles (09/2015 - 05/2013)|
|8.||Boulton, David W: 7 articles (03/2015 - 11/2011)|
|9.||Rohwedder, K: 6 articles (11/2015 - 04/2013)|
|10.||Iqbal, Nayyar: 6 articles (11/2015 - 01/2013)|
|1.||Body Weight (Weight, Body)
11/01/2015 - "Significantly greater reductions in FPG level, 2-h PPG level, and body weight were observed, and more patients achieved an HbA1c level of <7% (53 mmol/mol) with treatment with dapagliflozin versus placebo. "
01/01/2015 - "There were also significantly greater improvements for dapagliflozin twice daily groups versus placebo in FPG body weight and achievement of HbA1c level of <7%. "
11/01/2014 - "Dapagliflozin (5 and 10 mg) was well tolerated and effective in reducing HbA1c, FPG and body weight over 24 weeks in Japanese patients with T2DM inadequately controlled by diet and exercise."
10/01/2012 - "Dapagliflozin at doses of 1, 2.5 and 5 mg/day is effective in reducing glycaemic levels and body weight in treatment-naïve patients with type 2 diabetes. "
02/01/2015 - "Dapagliflozin improved glycaemic control, decreased body weight, and lowered blood pressure across the spectrum of T2DM disease, with maintenance of these benefits over time."
|2.||Type 2 Diabetes Mellitus (MODY)
05/01/2009 - "Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus."
01/01/2014 - "The efficacy of dapagliflozin combined with hypoglycaemic drugs in treating type 2 diabetes mellitus: meta-analysis of randomised controlled trials."
01/01/2014 - "Dapagliflozin as monotherapy in drug-naive Asian patients with type 2 diabetes mellitus: a randomized, blinded, prospective phase III study."
05/01/2013 - "Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double-blind, placebo-controlled trial."
05/01/2009 - "This 14-day study randomized patients with type 2 diabetes mellitus (T2DM) to four treatment groups receiving daily oral doses of 5-, 25-, or 100-mg doses of dapagliflozin or placebo, in order to evaluate glucosuria and glycemic parameters. "
|3.||Weight Loss (Weight Reduction)
06/01/2015 - "Dapagliflozin treatment is also associated with weight reduction and a decrease in blood pressure, both of which may be beneficial in patients with T2DM. "
07/01/2014 - "Dapagliflozin patients had significantly greater weight loss than placebo patients over 102 weeks (p < 0.05). "
10/01/2012 - "Mean FPG reduction was significantly greater for all dapagliflozin groups versus placebo (p < 0.02), as was mean weight reduction (p < 0.003). "
07/01/2014 - "Dapagliflozin-induced weight loss was associated with improvement in overall HRQOL. "
01/01/2013 - "Improvement in glycaemic control with a low risk of hypoglycaemia, concomitant weight loss and the potential of lowering of blood pressure make SGLT2 inhibition an attractive approach using dapagliflozin therapy. "
02/01/2015 - "Urinary tract and genital infections were more common with dapagliflozin, but responded to standard care and rarely led to study discontinuation. "
11/01/2015 - "Genital infections developed in more patients with dapagliflozin treatment (5%) than with placebo (0.6%). "
04/01/2015 - "Moreover, treatment with dapagliflozin does not increase risk for hypoglycaemia, but is associated with increased incidence of mild to moderate urinary and genital tract infections. "
12/01/2014 - "Dapagliflozin has a low risk of hypoglycaemia, although the incidence varies depending on background therapy, and genital mycotic infections (particularly in women) are the most common adverse events. "
08/01/2014 - "The incidence of hypoglycaemia was low with dapagliflozin, but it did increase the incidence of urogenital infections. "
01/01/2015 - "We conducted a pragmatic, open, 24-week study of treatment with 10 mg of oral dapagliflozin in patients with DM1 and chronic hyperglycemia. "
10/01/2010 - "Dapagliflozin lowered hyperglycemia in treatment-naive patients with newly diagnosed type 2 diabetes. "
04/01/2009 - "Dapagliflozin improved hyperglycemia and facilitates weight loss in type 2 diabetic patients by inducing controlled glucosuria with urinary loss of approximately 200-300 kcal/day. "
01/01/2014 - "Administration of 0.1 or 1.0 mg/kg of dapagliflozin ameliorated hyperglycemia, β-cell damage and albuminuria in db/db mice. "
12/01/2010 - "Dapagliflozin, apart from targeting hyperglycemia, also exerts beneficial effects on blood pressure, lipid profile, body weight and waist circumference. "
|6.||1- (glucopyranosyl)- 4- methyl- 3- (5- (4- fluorophenyl)- 2- thienylmethyl)benzene
|10.||Glycosylated Hemoglobin A (Glycosylated Hemoglobin)
|1.||Heterologous Transplantation (Xenotransplantation)